Publicaciones en colaboración con investigadores/as de Cleveland Clinic (38)

2024

  1. Anticoagulation Use and Endovascular Thrombectomy in Patients with Large Core Stroke: A Secondary Analysis of the SELECT2 Trial

    Annals of Neurology

  2. Bicaval TricValve Implantation in Patients With Severe Symptomatic Tricuspid Regurgitation: 1-Year Follow-Up Outcomes

    JACC: Cardiovascular Interventions, Vol. 17, Núm. 1, pp. 60-72

  3. Clinical relevance of intracranial hemorrhage after thrombectomy versus medical management for large core infarct: a secondary analysis of the SELECT2 randomized trial

    Journal of NeuroInterventional Surgery, pp. 1-8

  4. Endovascular Thrombectomy Treatment Effect in Direct vs Transferred Patients with Large Ischemic Strokes: A Prespecified Analysis of the SELECT2 Trial

    JAMA Neurology, Vol. 81, Núm. 4, pp. 327-335

  5. Endovascular Thrombectomy for Large Ischemic Stroke Across Ischemic Injury and Penumbra Profiles

    JAMA, Vol. 331, Núm. 9, pp. 750-763

  6. Endovascular thrombectomy plus medical care versus medical care alone for large ischaemic stroke: 1-year outcomes of the SELECT2 trial

    The Lancet, Vol. 403, Núm. 10428, pp. 731-740

  7. High PEEP with recruitment maneuvers versus Low PEEP During General Anesthesia for Surgery -a Bayesian individual patient data meta-analysis of three randomized clinical trials

    Anesthesiology

  8. LANDMARK comparison of early outcomes of newer-generation Myval transcatheter heart valve series with contemporary valves (Sapien and Evolut) in real-world individuals with severe symptomatic native aortic stenosis: a randomised non-inferiority trial

    The Lancet, Vol. 403, Núm. 10445, pp. 2695-2708

2023

  1. Alternative forms of portal vein revascularization in liver transplant recipients with complex portal vein thrombosis

    Journal of Hepatology, Vol. 78, Núm. 4, pp. 794-804

  2. Association of Endovascular Thrombectomy vs Medical Management with Functional and Safety Outcomes in Patients Treated beyond 24 Hours of Last Known Well: The SELECT Late Study

    JAMA Neurology, Vol. 80, Núm. 2, pp. 172-182

  3. Hypotension-Avoidance Versus Hypertension-Avoidance Strategies in Noncardiac Surgery An International Randomized Controlled Trial

    Annals of Internal Medicine, Vol. 176, Núm. 5, pp. 605-614

  4. Right heart remodelling after bicaval TricValve implantation in patients with severe tricuspid regurgitation

    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, Vol. 19, Núm. 5, pp. e450-e452

2022

  1. 6-Month Outcomes of the TricValve System in Patients With Tricuspid Regurgitation: The TRICUS EURO Study

    JACC: Cardiovascular Interventions, Vol. 15, Núm. 13, pp. 1366-1377

  2. Effect of a Perioperative Hypotension-Avoidance Strategy Versus a Hypertension-Avoidance Strategy on the Risk of Acute Kidney Injury: A Clinical Research Protocol for a Substudy of the POISE-3 Randomized Clinical Trial

    Canadian Journal of Kidney Health and Disease, Vol. 9

  3. Infective Endocarditis Caused by Staphylococcus aureus After Transcatheter Aortic Valve Replacement

    Canadian Journal of Cardiology, Vol. 38, Núm. 1, pp. 102-112

  4. Long-Term Intracoronary Structural and Vasomotor Assessment of the ABSORB Bioresorbable Vascular Scaffold

    American Journal of Cardiology, Vol. 168, pp. 55-63

  5. Mitral Valve Infective Endocarditis after Trans-Catheter Aortic Valve Implantation

    American Journal of Cardiology, Vol. 172, pp. 90-97

  6. Perivalvular Extension of Infective Endocarditis After Transcatheter Aortic Valve Replacement

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 75, Núm. 4, pp. 638-646

  7. Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery

    Trials, Vol. 23, Núm. 1

  8. Structural and Functional Evaluation of Coronary Arteries Treated With ABSORB Bioresorbable Vascular Scaffold at 5-Year Follow-Up

    American Journal of Cardiology, Vol. 182, pp. 1-7